Papers by Antonino Castellaneta
The unique immunologic environment of the liver, together with its anatomic location downstream o... more The unique immunologic environment of the liver, together with its anatomic location downstream of the gut, influences the maturation and function of its interstitial dendritic cell (DC) populations. These well-equipped, antigen-presenting cells play critical roles in regulation of innate and adaptive immunity. New information is emerging about the molecular regulation of liver DC maturation and function, and their tolerogenic potential, while new insight is being gained regarding interactions between liver DC and other immune effector cell populations (NK, NKT cells) in addition to T cells. During transplantation, factors that affect liver DC biology include ischemia-reperfusion injury, liver regeneration, viral infection and the actions of anti-inflammatory and immunosuppressive drugs. Herein, we review the molecular and cell biology of hepatic DC populations in relation to the regulation of alloimmune responses and liver transplant outcome.
Bookmarks Related papers MentionsView impact
JHEP Reports
Bookmarks Related papers MentionsView impact
Hepatobiliary & Pancreatic Diseases International
Bookmarks Related papers MentionsView impact
Therapeutic advances in chronic disease, 2018
Bookmarks Related papers MentionsView impact
Nephrology Dialysis Transplantation, 2015
Bookmarks Related papers MentionsView impact
Transplantation, 2010
Bookmarks Related papers MentionsView impact
Transplantation Research, 2016
Bookmarks Related papers MentionsView impact
American Journal of Transplantation
Bookmarks Related papers MentionsView impact
Journal of Crohn's and Colitis Supplements, 2007
Bookmarks Related papers MentionsView impact
Frontiers in bioscience (Elite edition), 2009
The unique immunologic environment of the liver, together with its anatomic location downstream o... more The unique immunologic environment of the liver, together with its anatomic location downstream of the gut, influences the maturation and function of its interstitial dendritic cell (DC) populations. These well-equipped, antigen-presenting cells play critical roles in regulation of innate and adaptive immunity. New information is emerging about the molecular regulation of liver DC maturation and function, and their tolerogenic potential, while new insight is being gained regarding interactions between liver DC and other immune effector cell populations (NK, NKT cells) in addition to T cells. During transplantation, factors that affect liver DC biology include ischemia-reperfusion injury, liver regeneration, viral infection and the actions of anti-inflammatory and immunosuppressive drugs. Herein, we review the molecular and cell biology of hepatic DC populations in relation to the regulation of alloimmune responses and liver transplant outcome.
Bookmarks Related papers MentionsView impact
Frontiers in bioscience (Elite edition)
The unique immunologic environment of the liver, together with its anatomic location downstream o... more The unique immunologic environment of the liver, together with its anatomic location downstream of the gut, influences the maturation and function of its interstitial dendritic cell (DC) populations. These well-equipped, antigen-presenting cells play critical roles in regulation of innate and adaptive immunity. New information is emerging about the molecular regulation of liver DC maturation and function, and their tolerogenic potential, while new insight is being gained regarding interactions between liver DC and other immune effector cell populations (NK, NKT cells) in addition to T cells. During transplantation, factors that affect liver DC biology include ischemia-reperfusion injury, liver regeneration, viral infection and the actions of anti-inflammatory and immunosuppressive drugs. Herein, we review the molecular and cell biology of hepatic DC populations in relation to the regulation of alloimmune responses and liver transplant outcome.
Bookmarks Related papers MentionsView impact
Current Opinion in Organ Transplantation, 2010
A fundamental goal in transplantation is the establishment of allograft function without ongoing ... more A fundamental goal in transplantation is the establishment of allograft function without ongoing immunosuppression. Robust allograft tolerance has been established in experimental transplantation models, whereas clinical operational tolerance has been described most frequently following human liver transplantation. Clinical assessment of tolerance has been limited to laboratory evaluation of organ function. Additional tools include graft monitoring through biopsy and blood sampling for biomarker analysis. Current biomarkers under assessment in recent years include dendritic cell subsets, regulatory T cells, antidonor antibodies, and gene polymorphisms. Emerging microarray analysis that is being prospectively validated will also be reviewed. A further tool in the characterization of the tolerant patient will be the accurate enrollment of such patients into a multicenter registry that will prospectively follow the natural history of the patient withdrawn from immunosuppression and help facilitate the entry of interested patients to mechanistic and immune monitoring trials. The International Solid Organ Transplant Tolerance Registry (www.transplant-tolerance.org) will be briefly described. Effective biomarker characterization of the operationally tolerant liver allograft recipient would allow earlier, well tolerated, prospective drug withdrawal with the goal of extending the potential benefits of drug minimization to an increasing number of patients in a more predictable fashion.
Bookmarks Related papers MentionsView impact
Bookmarks Related papers MentionsView impact
Transplantation Journal, 2010
Bookmarks Related papers MentionsView impact
Transplantation Journal, 2010
Bookmarks Related papers MentionsView impact
Transplant International, 2014
Response to interferon-based therapies in HCV recurrence after liver transplantation (LT) is unsa... more Response to interferon-based therapies in HCV recurrence after liver transplantation (LT) is unsatisfactory, and major safety issues aroused in preliminary experience with boceprevir and telaprevir. As transplant community identified HCV viral clearance as a critical matter, efficacious and safe anti-HCV therapies are awaited. The aim of this study was to assess efficacy and safety of intravenous silibinin monotherapy in patients with established HCV recurrence after LT, nonresponders to pegylated interferon and ribavirin. This is a single center, prospective, randomized, parallel-group, double-blind, placebo-controlled, phase 2 trial including 20 patients randomly assigned (3:1) to receive daily 20 mg/kg of intravenous silibinin or saline as placebo, for 14 consecutive days. On day 14 of treatment, viral load decreased by 2.30 ± 1.32 in silibinin group versus no change in the placebo group (P = 0.0002). Sixteen days after the end of the treatment, viral load mean values were similar to baseline. Treatment resulted well tolerated apart from a transient and reversible increase in bilirubin. Neither changes in immunosuppressant through levels nor dosage adjustments were necessary. Silibinin monotherapy has a significant antiviral activity in patients with established HCV recurrence on the graft not responding to standard therapy and confirms safety and tolerability without interaction with immunosuppressive drugs (ClinicalTrials.gov number: NCT01518933).
Bookmarks Related papers MentionsView impact
Journal of Viral Hepatitis, 2003
Bookmarks Related papers MentionsView impact
Journal of Surgical Research, 2011
Bookmarks Related papers MentionsView impact
The Journal of Immunology, 2009
Bookmarks Related papers MentionsView impact
The Journal of Immunology, 2004
Bookmarks Related papers MentionsView impact
Uploads
Papers by Antonino Castellaneta